Effective January 1st, the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List and Commercial Health Insurance Innovative Drug List (2025)" has been officially implemented. Within this new list, three innovative drugs independently developed by SKB BIO-B (06990)—Lucansatuzumab (Jiatailai®), Cetuximab N01 (Datailai®), and Tagolizumab (Ketailai®)—have successfully been included. For patients with advanced triple-negative breast cancer and those with non-small cell lung cancer who have failed EGFR-TKI therapy, traditional treatment options have often yielded limited effectiveness. As the first domestically developed ADC (antibody-drug conjugate) in China to receive full approval for marketing, Lucansatuzumab was officially approved in November 2024 for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in patients who have received at least two prior systemic therapies (including at least one for advanced or metastatic disease), thereby opening a new treatment paradigm for patients with second-line or later advanced TNBC. In March 2025, a second new indication for the drug was successfully approved for the treatment of EGFR mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has progressed following EGFR-tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy, effectively filling a gap in the treatment options available for later-line therapy in this area. The inclusion of these three drugs in the national reimbursement list not only reduces the previously high treatment costs but also tangibly alleviates the financial burden on patients through the reimbursement mechanism, making this "hope for life" genuinely accessible. Addressing the unmet clinical needs and the reduction in treatment costs, Dr. Ge Junyou, General Manager and CEO of SKB BIO-B, stated, "When you know your innovative research成果 might change the treatment landscape of a disease area and fill a currently untreatable gap, that sense of mission transcends any commercial consideration. Although there are already similar therapeutic products within the reimbursement drug list, we are willing to promote domestic substitution at a more affordable price to prevent patients from falling into or returning to poverty due to illness."